A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination With TH-302 vs. Pemetrexed in Combination With Placebo as Second-line Chemotherapy for Advanced Non-Squamous, Non-Small Cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 27 Sep 2017
Price : $35 *
At a glance
- Drugs Evofosfamide (Primary) ; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Sponsors Threshold Pharmaceuticals
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 06 Jun 2016 Results published in Threshold Pharmaceuticals media release.
- 01 Jun 2016 Status changed from suspended to discontinued.